of post-SRS brain necrosis specific to AVM treatment has been found to correlate with the volume of normal brain surrounding the irradiated target area, which is exposed to 12 Gy. 3, 6, 7, 18, 19 The technique involves first treating a portion of the target volume (typically the area of the ni dus close to feeder veins) with the intended SRS dose, followed by treatments of remaining portions of the tar get volume in a sequential manner.
With the recent introduction of precision SRT tech nologies, such as the Gamma Knife Extend system, and LINACbased modalities, such as the CyberKnife, hypo fractionated SRT, in which a high dose is delivered to the target volume in 5 or fewer fractions, has been pro posed. 4, 15, 16, 24, 25 In particular, physician experiences with CyberKnife 1 (Accuray) treatments that have been report ed in the literature indicate encouraging preliminary re sults. 5, 20, 23 Highprecision volumestaged Gamma Knife surgery and equivalent hypofractionation dose schedules for treating large arteriovenous malformations While a potential advantage to using hypofraction ation is the reproducibility of targeting the same area without the risk of dynamic changes that may occur be tween treatment delivery sessions in a multistaged treat ment, a key challenge is how to deliver a sufficiently high total dose to produce efficacy comparable to that of singlefraction SRS. 9 In addition, while hypofractionated treatments theoretically allow better sparing of normal brain tissue and target dose delivery compared with vol ume-staged treatments, it is difficult to quantify a com parison between a traditional hypofractionated regimen and a volumestaged regimen.
The goal of our study was twofold: 1) to develop a vol umestaged technique with accuracy comparable to that of existing SRT delivery; and 2) to develop datadriven hypofractionated treatment protocols by comparing bio logically equivalent normal brain 12Gy volumes from a hypofractionated treatment with those of a volumestaged Gamma Knife treatment.
Methods
Seven children with AVMs who had undergone vol umestaged treatment with the Gamma Knife Perfexion (Elekta AB) at the University of California, San Francisco, were selected for the study. The mean target volume for these cases was 11.3 ± 2.2 cm 3 (range 8.0-15.0 cm 3 ). All patients underwent 2 volumestaged GKSs. The techni cal details of our volumestaging technique have been previously described. 18 In brief, AVM target volumes are divided into 2 approximately equal portions, with each portion treated to a dose of 17 Gy or higher; the time in terval between the 2 treatments is typically 6-9 months. To match the 2 volumestaged treatment plans, we devel oped a 3dimensional image registration plus a landmark based frame coordinate transformation procedure. The key goal of the procedure was to translate the Gamma Knife shot or isocenter coordinates from 1 frame system to another. Our procedure involved the following steps: 1) at both sessions, define the time-of-flight MR target image according to the treatmentday frame system; 2) at the second treatment session, coregister the MRI study obtained that day with the initialframe MRI study ob tained on the first treatment day via a voxel-based mu tual information matching method; 3) identify the same landmark coordinates on the 2 imaging studies described in the first 2 steps; and 4) translate the radiation shot positions from the earlier treatment based on identified landmarks, which intrinsically specifies the 2 frame sys tems. Implementation of the fourth step is similar to that described in a previous study, 18 except that the shot trans formation matrix is determined via a nonlinear gradient search algorithm in an Excel spreadsheet with an embed ded solver package (the spreadsheet is available and free from the corresponding author upon request).
For each volumestaged case, a corresponding Gam ma Knife Extend plan was reconstructed. In addition, the imaging studies plus associated contour lines were exported via the DICOMRT protocol using the Leksell GammaPlan image export tool (version 9.0, Elekta AB). The exported images and contour lines were then import ed into the CyberKnife MultiPlan workstation (version 3.5, Accuray) for independent treatment planning. Since both Gamma Knife Extend system and CyberKnife treat ments require a CT study for dose computation, a refer ence phantom CT study was used to merge with the MRI studies obtained in the pediatric patients for treatment plan optimization in a consistent manner. The CyberKnife treatment plans were optimized via the sequential inverse optimization routine. For all treatment plans, dosevol ume constraints were imposed to produce a comparable dose to surrounding normal brain tissue while achieving the same target volume coverage as the corresponding Gamma Knife Extend system treatment plans.
Once a hypofractionated treatment plan had been developed, the hypofractionated total dose for each case was determined to produce an identical volume of normal brain receiving 12 Gy-the 12Gy isodose volume minus the target volume, in biological equivalence to the cor responding volumestaged Gamma Knife treatment plan. For the purpose of illustration, suppose that a compos ite volume receiving 12 Gy in a volumestaged Gamma Knife treatment plan was found to equal 15.0 cm 3 , then when setting the target dose for an nfraction SRT treat ment, we would first adjust the prescribed dose value such that the plan produced exactly 15 cm 3 of 12 Gy according to the biologically effective dose. In the context of the standard linear quadratic model, this means that 15 cm Furthermore, the prescribed dose can be also be es timated based on an analytical model from our previous study, 17 in which the prescribed target dose (d 0 ) relating to a nearby peripheral isodose volume for a solitary tar get is given as follows:
, where V 0 is the prescribed isodose volume, V T is the isodose volume cor responding to d T , and g is the power index approximately equal to −1.5 for radiosurgical deliveries.
Using the aforementioned example, suppose a target of V 0 = 11 cm 3 and a volume receiving 12 Gy of V T = 15.0 cm 
Results
Our overall accuracy in the volumestage frame matching for all the cases was a mean of 0.33 ± 0.09 mm with the maximum less than 0.5 mm. Such a result in dicated that the wholeprocedure accuracy of a volume staged SRT agrees with the accuracy of the standard GKS to within 0.5 mm, a value approaching the mechanical accuracy of the latest Gamma Knife Perfexion system. 14 The isodose distributions of a volumestaged Gamma Knife-treated AVM case are shown in Fig. 1A and B. The corresponding hypofractionated treatment plans are shown in Fig. 1C (CyberKnife) and Fig. 1D (Gamma Knife Extend system). The composite 12Gy isodose vol ume (the isodose volume receiving 12 Gy, which is ar rived at by summing the dose distributions of Fig. 1A  and B 
The treatment plan summary for all case results is shown in Table 1 . Because of the conformity and target coverage constraints imposed on the CyberKnife SRT and Gamma Knife Extend SRT plans for this study, the resulting 12Gy isodose volumes agreed within 0.2 cm 3 between the 2 systems and these values are shown in Table 1 . For all cases, a reduction of 18.7% ± 7.3% in the equivalent single fractional dose was observed for the SRT plans to maintain the same 12Gy isodose volumes as those of the volumestaged SRS treatments. Such a dif ference was statistically significant (p = 0.0014) based on the paired 2tail Student ttest. The mean composite 12 Gy isodose volume for the staged treatments was 22.6 ± 5.6 cm 3 versus 28.6 ± 6.9 cm 3 for the SRTs. The mean 12Gy isodose volume to the ventricles ad jacent the targets was 0.35 ± 0.48 cm 3 for the staged treat ments versus 0.63 ± 1.04 cm 3 for the SRTs (p = 0.245). Subtracting the enclosed portion of the ventricle volumes and the target volumes from the total 12Gy isodose vol umes, as listed in Table 1 , we obtained mean normal brain 12Gy volumes of 22.2 ± 5.5 cm 3 for the staged treatments and 27.9 ± 6.7 cm 3 for the hypofractionated SRTs (p = 0.002).
The prescribed radiation dose guideline for SRTs, as derived from the studied cases, is shown in Fig. 2 . The er ror bars on the plot represent 1 standard deviation value. From the results in Fig. 2 , dose variations among indi vidual cases tend to increase nonlinearly with increasing number of fractions. Based on the fitted curve, the most common 5fractionation dose scheme for an SRT would be 27.3 Gy.
Discussion
We determined hypofractionation treatment schemes for large AVMs that would yield equivalent sparing of normal brain tissue to that of volumestaged GKS. The doses that our model derived are fundamentally based on the biologically equivalent 12Gy singlefraction isodose volume as the predictor of treatmentrelated toxicity. The total doses plotted in Fig. 2 (for example, 27 .0 Gy in 5 fractions and 24.0 Gy in 4 fractions) are in fact consis tently lower than the current hypofractionated schemes reported in the literature. 22 For example, Xiao et al. 24 treated 20 large AVMs with 25-30 Gy in 5-6 Gy frac tions and found an improvement in efficacy when using 30 Gy. Lindvall et al. 15 examined 66 patients treated with 30-35 Gy in 5 fractions and found a higher rate of oblit eration in patients treated with 35 Gy than in those treat ed with 30 Gy (88% vs 78%); however, the authors noted that all patients who experienced symptomatic necrosis belonged to the group treated with 35 Gy. Based on our calculations, 27 Gy may be the appropriate dose to strike a balance between efficacy and toxicity. However, more clinical data with hypofractionated treatments of large AVMs are required. These model calculations need to be further validated before general conclusions can be made about dose efficacy and the potential superiority of hy pofractionated treatments over volumestaged treatments.
Our choice of the 12Gy isodose volume as a dose sur rogate for normal brain tissue toxicity is well supported by the literature. In our previous studies we demonstrated similar physical peripheral isodose volume characteris tics for a solitary target regardless of the isodose volume chosen (for example, 8Gy, 10Gy, or 12Gy isodose vol ume) or the SRS treatment technology (Gamma Knife, CyberKnife or LINACbased systems 17 ). Therefore, using a single peripheral isodose volume (such as the 12Gy volume in our study) is sufficient as a surrogate for the overall 3dimensional peripheral dose distribution inside normal brain tissue surrounding a radiosurgical target and, therefore, is not considered a limitation of the study.
In addition, the empirical parameter of a/b = 3 Gy was adopted for the normal brain in our study. Such a value is well supported in the literature, 11 and small varia tions in the a/b value, such as 10%, were found to in troduce negligible changes in the curve shown in Fig. 2 . Nonetheless, the application of the linear quadratic model for hypofractionated treatments has been a subject of de bate, despite the fact that no other model has yet to be shown and accepted as superior. 2 One potential limitation of this study is the inabil ity to account for the relatively long time period (6-9 months) between staged Gamma Knife treatments within the standard linear quadratic model. Our calculations have assumed that the normal brain sparing provided by such an extended time is identical to that provided by daily hypofractionated SRT delivery, but this is unlikely to be accurate. If, on the other hand for example, an ex tended time period was found to be more beneficial for sparing normal brain compared with dailyadministered SRT delivery as expected, then the general conclusion of this study regarding the benefits of staged treatments would be further strengthened.
Conclusions
The capability of hypofractionated SRTs for large AVMs to spare normal brain is equivalent to that of volumestaged SRS. However, the hypofractionated SRT dose necessary for this was found to be significantly low er than doses reported in current clinical practices. It is only with future clinical comparisons that we will know whether more patients have been subjected to higher rates of radiation necrosis than currently observed using vol umestaged treatments. 
